Dubray B, Delanian S, Lefaix J L
Département d'oncologie-radiothérapie, institut Curie, Paris, France.
Cancer Radiother. 1997;1(6):744-52. doi: 10.1016/s1278-3218(97)82951-4.
Late damages to the skin and subcutaneous tissues are almost inescapable because of the high skin doses required in the irradiation of breast tumours. While the clinical and histological descriptions date back to the first decades of the therapeutic use of ionising radiation, the recent advances in cellular and molecular biology have significantly contributed to the increased understanding of late skin injury mechanisms. In particular, sub-cutaneous fibrosis appears to be the partly reversible results of a continuous and self-maintained local process, possibly sensitive to therapeutic intervention. A second very active research avenue is the development of biologic assays potentially able to predict the probability of increased normal tissue injury after irradiation in individual patients. Such a test would allow the adaptation of the treatment modalities to the radiobiological behaviour of normal tissues. To date, these expectations have not been met. The quality of the irradiation and its modalities (total dose, fractionation, inter fraction interval) remain the main ways to achieve an optimal functional and cosmetic outcome.
由于乳腺肿瘤放疗需要高剂量的皮肤照射,皮肤和皮下组织的晚期损伤几乎不可避免。虽然临床和组织学描述可追溯到电离辐射治疗应用的最初几十年,但细胞和分子生物学的最新进展显著增进了对晚期皮肤损伤机制的理解。特别是,皮下纤维化似乎是一个持续且自我维持的局部过程的部分可逆结果,可能对治疗干预敏感。另一个非常活跃的研究方向是开发生物检测方法,有望预测个体患者放疗后正常组织损伤增加的可能性。这样的检测将使治疗方式能够根据正常组织的放射生物学行为进行调整。迄今为止,这些期望尚未实现。照射的质量及其方式(总剂量、分割方式、分次间隔)仍然是实现最佳功能和美容效果的主要途径。